Nanjing, China — June 1, 2025 — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide plus platinum-ba

Nanjing, China — April 24, 2025 — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) today announced that two of its innovative oncology assets, LBL-024 and LBL-007, have been selected for oral and poster presentations, respectively, at the 2025 American Society of Clinical Oncology (ASCO) Annual Mee

The 2025 American Association for Cancer Research® (AACR) annual meeting will be held in Chicago, USA, from April 25 to 30. Nanjing Leads Biolabs (Leads Biolabs) will unveil the latest research results of four preclinical pipelines during a poster session, including LBL-054-CD3 (an anti-CDH17 and CD

In February 2025, the Phase Ib/II clinical trial results of LBL-007, a novel LAG-3 antibody independently developed by Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs"), was published in the prestigious Journal of Hematology & Oncology (Impact Factor: 29.9). This study, le

The 66th Annual Meeting of the American Society of Hematology (ASH 2024) will take place in San Diego, California, from December 7th to 10th. LBL-034, a humanized bispecific T-cell engager targeting both GPRC5D and CD3 which is independently developed by Nanjing Leads Biolabs Co., Ltd. (hereinafter

NANJING, China, November 22, 2024 -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for the treatment of neuroendocrine cancer

Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody

NANJING, China, November 1st, 2024--Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently developed by Leads Biolabs with global intellectual property r

NANJING, China, October 9, 2024--Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently develop

NANJING, China, September 27, 2024— Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the most recent clinical research findings of LBL-024, an anti-PD-L1/4-1BB bispecific antibody, and LBL-007, an anti-LAG-3 antibody, were showcased in an